NOVELETTE E THOMPSON
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism FT. LAUDERDALE, FL NPI 1962412296
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism FL Medtronic, Inc. All categories
General Payments — all program years on this page
$4,091.53
- Category: General Payments
- Program years: PY2018–2024
- Record count: 154
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $2,338.15 across 77 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,726.59 | 72 |
| Travel and Lodging | $611.56 | 5 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Medtronic, Inc. | $847.66 | 13 |
| Novo Nordisk AS | $161.76 | 8 |
| BETA BIONICS, INC. | $142.91 | 3 |
| Radius Health, Inc. | $121.58 | 4 |
| Lilly USA, LLC | $118.23 | 5 |
| Corcept Therapeutics | $116.36 | 6 |
| Amgen Inc. | $91.52 | 5 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $69.97 | 3 |
| Tandem Diabetes Care, Inc. | $69.61 | 3 |
| Xeris Pharmaceuticals, Inc. | $66.94 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $63.14 | 3 |
| DEXCOM, INC. | $60.57 | 3 |
| Exact Sciences Corporation | $59.28 | 2 |
| SANOFI-AVENTIS U.S. LLC | $44.69 | 2 |
| MannKind Corporation | $44.52 | 2 |
| Abbott Laboratories | $43.00 | 2 |
| Insulet Corporation | $28.56 | 1 |
| Verity Pharmaceuticals Inc. | $28.32 | 1 |
| Alexion Pharmaceuticals, Inc. | $25.54 | 1 |
| Neurocrine BioSciences, Inc. | $23.84 | 1 |
| Astellas Pharma US Inc | $23.40 | 1 |
| Esperion Therapeutics, Inc. | $20.08 | 1 |
| CeQur Corporation | $19.20 | 1 |
| Alvogen Inc | $18.10 | 1 |
| ABBVIE INC. | $15.99 | 1 |
| Acella Pharmaceuticals, LLC | $13.38 | 1 |
By program year
Records — PY2024 (77)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.